Literature DB >> 6298890

U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists.

P F Von Voigtlander, R A Lewis.   

Abstract

1. U-50,488 is a structurally novel, non-mu opioid. In the present experiments it was compared to the reputed kappa opioid agonists, ketazocine, ethylketocyclazocine and bremazocine as regards analgesic cross tolerance to morphine and U-50,488, antagonism of analgesia by naloxone and MR-2266 (in vivo pA2 determination), and narcotic antagonist properties (antagonism of morphine analgesia and precipitation of abstinence in morphine-dependent mice). 2. The analgesic mechanism of bremazocine was similar to that of U-50,488 but the former compound had, in addition, considerable mu-antagonist activity. The analgesic mechanisms of the ketazocines were less selective; both shared both mu and kappa agonist properties. U-50, 488, however, had no such mu agonist or antagonist effects and thus is a more selective kappa agonist. 3. This compound and its congeners may prove useful in the elucidation of the functions of kappa receptors in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6298890     DOI: 10.1016/s0278-5846(82)80130-9

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  27 in total

1.  κ-Opioid receptors within the nucleus accumbens shell mediate pair bond maintenance.

Authors:  Shanna L Resendez; Morgan Kuhnmuench; Tarin Krzywosinski; Brandon J Aragona
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

Review 2.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

3.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Authors:  Yunyun Yuan; Saheem A Zaidi; David L Stevens; Krista L Scoggins; Philip D Mosier; Glen E Kellogg; William L Dewey; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

4.  Kappa opioid receptor signaling protects cartilage tissue against posttraumatic degeneration.

Authors:  Ling Wu; Shu Zhang; Ruzanna Shkhyan; Siyoung Lee; Francesca Gullo; Claire D Eliasberg; Frank A Petrigliano; Kai Ba; Jing Wang; Yunfeng Lin; Denis Evseenko
Journal:  JCI Insight       Date:  2017-01-12

5.  Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.

Authors:  J H Broadbear; S S Negus; E R Butelman; B R de Costa; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

6.  Role of central opiate receptor subtypes in the circulatory responses of awake rabbits to graded caval occlusions.

Authors:  R G Evans; J Ludbrook; A F Van Leeuwen
Journal:  J Physiol       Date:  1989-12       Impact factor: 5.182

7.  Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.

Authors:  Antony D Abraham; Selena S Schattauer; Kathryn L Reichard; Joshua H Cohen; Harrison M Fontaine; Allisa J Song; Salina D Johnson; Benjamin B Land; Charles Chavkin
Journal:  J Neurosci       Date:  2018-08-03       Impact factor: 6.167

8.  A cell-based, high-throughput homogeneous time-resolved fluorescence assay for the screening of potential κ-opioid receptor agonists.

Authors:  Yue Wang; Ming Yan; Guang-Yao Zheng; Ling He; Huan Yang
Journal:  Acta Pharmacol Sin       Date:  2014-06-16       Impact factor: 6.150

9.  The role of serotonergic receptors in the effects of mu opioids in squirrel monkeys responding under a titration procedure.

Authors:  K R Powell; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

10.  Effects of the selective kappa-opioid agonist U50,488 upon the electrical activity of supraoptic neurones in morphine-tolerant and morphine-naive rats.

Authors:  K M Pumford; J A Russell; G Leng
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.